Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HALOTHANE vs DESFLURANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Halothane is a volatile halogenated hydrocarbon anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits NMDA and nicotinic acetylcholine receptors, leading to neuronal hyperpolarization and general anesthesia.
Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.
Induction and maintenance of general anesthesia,Sedation in intensive care (off-label),Status asthmaticus (off-label, due to bronchodilation)
Maintenance of general anesthesia for inpatient and outpatient surgery in adults and children,Induction of anesthesia in adults and pediatric patients
Induction: 0.5-3% in oxygen or oxygen-nitrous oxide mixture, titrated to effect; Maintenance: 0.5-2% in oxygen or oxygen-nitrous oxide mixture.
Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).
Terminal elimination half-life approximately 5-10 hours post-anesthesia, with a slower terminal phase (up to 3 days) due to redistribution from fat stores. Clinically, washout is rapid initially but prolonged exposure in obese patients may lead to detectable levels for days.
Terminal elimination half-life is 3.5–4.5 minutes (context-sensitive half-life after prolonged anesthesia can be longer due to distribution, but true elimination is rapid due to low blood/gas partition coefficient).
Halothane is metabolized in the liver primarily by cytochrome P450 2E1 (CYP2E1) to trifluoroacetic acid and bromide ion; reductive metabolism also produces chloride ions and free radicals.
Minimal hepatic metabolism (<0.02%) via CYP2E1; primarily eliminated unchanged by the lungs.
Primarily eliminated via pulmonary excretion (60-80% unchanged); approximately 20% metabolized in liver via CYP2E1, with metabolites excreted renally (trifluoroacetic acid, chloride, bromide). Only about 0.5% excreted unchanged in urine. Fecal excretion negligible.
Primarily eliminated via exhalation; minimal hepatic metabolism (<0.02%). Renal excretion of metabolites negligible. >99% excreted unchanged by lungs.
Approximately 20-30% bound to plasma proteins, primarily albumin and lipoproteins.
Approximately 5–10% bound to plasma proteins (primarily albumin).
Volume of distribution at steady state (Vdss) approximately 2-5 L/kg; large Vd indicates extensive tissue distribution, especially to adipose tissue, brain, and muscle.
Vd approximately 0.2–0.5 L/kg (small, reflecting limited tissue distribution; consistent with lipophilic but rapidly equilibrating profile).
100% bioavailable via inhalation (only route of administration). Oral bioavailability not applicable.
Inhalation: ~100% bioavailable into systemic circulation via lungs.
No specific dose adjustment required for renal impairment; use with caution due to potential nephrotoxicity from fluoride ions.
No dosage adjustment required for renal impairment; desflurane is minimally metabolized and not dependent on renal excretion.
Child-Pugh Class A: no adjustment; Child-Pugh Class B and C: avoid use; contraindicated in patients with hepatic impairment or history of halothane-induced hepatotoxicity.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential for increased hepatotoxicity, but no dose modification guidelines exist.
Induction: 0.5-2% in oxygen or oxygen-nitrous oxide mixture, gradually increased; Maintenance: 0.3-1.5% as needed. Use lowest effective dose.
Induction: 3-12% inhaled (up to 18% for mask induction); maintenance: 3-6% inhaled; adjust based on age and response; higher MAC requirements in infants.
Reduce dose by 25-50% due to increased sensitivity and reduced clearance; monitor hemodynamics closely.
Reduce dose by 20-30% compared to younger adults; typical maintenance 2-5% inhaled; lower MAC (approx 4.5% at 65 years); monitor for hypotension and bradycardia.
Halothane can cause hepatic necrosis, which may be fatal. Fatalities have occurred in patients with previous halothane exposure. Avoid repeat exposure within 3-6 months.
Desflurane is not indicated for induction of general anesthesia in pediatric patients due to a high incidence of laryngospasm and upper airway adverse events.
Hepatotoxicity (halothane hepatitis), malignant hyperthermia, cardiac arrhythmias (sensitizes myocardium to catecholamines), respiratory depression, hypotension, increased intracranial pressure.
Malignant hyperthermia,Respiratory depression and airway complications,Cardiovascular depression (hypotension, bradycardia),QT prolongation,Hepatotoxicity (rare),Rising carbon monoxide levels with dry absorbents,Neurotoxicity in pediatric patients,Renal toxicity (rare)
Hypersensitivity to halothane, known or suspected susceptibility to malignant hyperthermia, history of unexplained jaundice or fever after halothane, hepatic dysfunction following previous halothane exposure, pregnancy (relative, especially first trimester).
Known sensitivity to desflurane or other halogenated anesthetics,History of malignant hyperthermia,Refractory hypovolemia,Increased intracranial pressure (relative),Concomitant use with adrenergic agents (risk of arrhythmias)
No specific food interactions. However, fasting is required before anesthesia to reduce aspiration risk. Alcohol should be avoided for at least 24 hours post-anesthesia due to additive CNS depression.
No known food interactions. However, patients should follow preoperative fasting guidelines (nil per os for at least 2 hours for clear liquids and 6-8 hours for solid foods) to reduce the risk of pulmonary aspiration during anesthesia.
Halothane is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects, but adequate human studies are lacking. First trimester exposure is associated with a potential increased risk of congenital malformations based on limited epidemiological data. Second and third trimester use may cause fetal depression and uterine atony; prolonged exposure can lead to neonatal respiratory depression. Avoid use during pregnancy unless clearly needed.
Desflurane is not associated with major congenital malformations in the first trimester, but use in the second and third trimesters may cause fetal depression, decreased fetal heart rate variability, and neonatal respiratory depression. It is pregnancy category B, but caution is advised.
Halothane is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.4. Due to low oral bioavailability, risks to the nursing infant are minimal. However, caution is advised as effects on the infant have not been fully studied. Consider pumping and discarding milk for 24-48 hours after anesthesia to minimize exposure.
Desflurane is minimally excreted into breast milk; M/P ratio is unknown. It is considered compatible with breastfeeding due to rapid elimination from the mother and low oral bioavailability in the infant. However, monitor for neonatal sedation.
No specific dose adjustment is recommended, but pregnancy alters pharmacokinetics: increased volume of distribution and decreased protein binding may require higher initial doses to achieve desired anesthetic depth. However, due to increased sensitivity to myocardial depression and uterine relaxation, use the minimum effective dose. Reduce concentration as needed to maintain uterine perfusion and avoid fetal hypoxia.
No specific dose adjustment for desflurane in pregnancy, but the minimum alveolar concentration (MAC) is reduced by approximately 25-40% due to increased progesterone and other factors. Lower doses may be required to achieve desired anesthetic depth.
Halothane is a volatile halogenated hydrocarbon anesthetic. It sensitizes the myocardium to catecholamines, increasing risk of arrhythmias; avoid epinephrine use. Associated with halothane hepatitis (immune-mediated hepatotoxicity), especially with multiple exposures. Malignant hyperthermia trigger; have dantrolene ready. Use with caution in patients with increased intracranial pressure as it can elevate ICP. Use with low fresh gas flows to minimize pollution and cost.
Desflurane has the lowest blood-gas partition coefficient among volatile anesthetics, resulting in the fastest onset and emergence. Its pungent odor limits use for inhalation induction, especially in children. Due to its high vapor pressure, a specialized heated vaporizer is required. Desflurane can cause sympathetic nervous system activation at high concentrations, leading to tachycardia and hypertension. It is metabolized minimally (0.02%), but can produce carbon monoxide when exposed to dried CO2 absorbents; desiccated absorbents should be avoided. Malignant hyperthermia risk is present, so dantrolene should be available.
This medication will make you unconscious for surgery. You will not feel pain or remember the procedure.,You must fast before anesthesia; do not eat or drink for at least 6-8 hours before surgery.,Tell your anesthesiologist about any liver problems or previous reactions to anesthesia.,Notify your doctor if you have a personal or family history of malignant hyperthermia.,Avoid alcohol for at least 24 hours after anesthesia.,Do not drive or operate machinery for 24 hours after receiving halothane.
You will receive desflurane gas through a mask or breathing tube to keep you asleep during surgery.,Desflurane has a strong smell; you may notice an odor as you fall asleep.,You will wake up quickly after the anesthetic is stopped, but you may feel drowsy or confused initially.,Potential side effects include nausea, vomiting, shivering, and a temporary increase in heart rate or blood pressure.,Inform your doctor if you have a personal or family history of malignant hyperthermia (a severe reaction to anesthesia).,Do not eat or drink before surgery as instructed to prevent aspiration.
"Efonidipine, a dihydropyridine calcium channel blocker, inhibits L-type and T-type calcium channels, leading to vasodilation and reduced myocardial contractility. Halothane, a volatile inhalational anesthetic, depresses myocardial function and sensitizes the myocardium to catecholamines, increasing the risk of arrhythmias. Concurrent use can result in additive negative inotropic effects and profound hypotension, potentially leading to cardiovascular collapse."
"Halothane, a volatile anesthetic, can inhibit the cytochrome P450 enzyme CYP2B6, which is primarily responsible for the metabolism of bupropion, an antidepressant and smoking cessation aid. This inhibition leads to decreased clearance of bupropion, resulting in elevated plasma concentrations that increase the risk of dose-dependent adverse effects such as seizures, anxiety, and insomnia. Clinically, patients may exhibit heightened neuropsychiatric toxicity and reduced seizure threshold, particularly during and after halothane anesthesia."
"Halothane, a volatile halogenated anesthetic, inhibits cytochrome P450 (CYP) isoenzymes, particularly CYP2C19, which is crucial for the hepatic bioactivation of clopidogrel to its active metabolite. Concomitant administration can lead to reduced plasma concentrations of the active thiol metabolite of clopidogrel, diminishing its antiplatelet effect and increasing the risk of thrombotic events such as stent thrombosis or myocardial infarction in patients with coronary artery disease. This interaction is especially significant in patients undergoing surgery where halothane is used for anesthesia while clopidogrel is indicated for recent acute coronary syndrome or percutaneous coronary intervention."
"Concurrent use of buspirone and desflurane may potentiate the hypotensive and bradycardic effects of desflurane, increasing the risk of hemodynamic instability during anesthesia induction or maintenance. Buspirone's serotonergic activity can also lower seizure threshold, potentially interacting with the anesthetic properties of desflurane to cause perioperative seizures or arrhythmias. Clinically, this combination requires careful cardiovascular monitoring and dose adjustment of desflurane to avoid excessive hypotension, bradycardia, or delayed emergence."
"Concomitant use of Desflurane and Triprolidine may lead to enhanced central nervous system (CNS) depression and potential respiratory compromise. Desflurane, a volatile anesthetic, depresses the CNS and respiratory drive, while Triprolidine, a first-generation antihistamine, adds sedative and anticholinergic effects. This synergistic interaction increases the risk of excessive sedation, hypotension, and respiratory depression, particularly during induction or recovery from anesthesia. Clinically, patients may experience prolonged emergence, worsened cognitive function, and increased need for ventilatory support."
"Concomitant administration of desflurane, a volatile halogenated anesthetic, with oxprenolol, a non-selective beta-adrenergic receptor antagonist with intrinsic sympathomimetic activity, can lead to additive negative inotropic and chronotropic effects on the myocardium, resulting in significant hypotension and bradycardia. This interaction occurs because desflurane depresses myocardial contractility and heart rate directly, while oxprenolol blocks compensatory sympathetic responses, potentially compromising cardiac output and tissue perfusion. Clinicians should be vigilant for exaggerated cardiovascular depression, especially during induction or changes in anesthetic depth."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HALOTHANE vs DESFLURANE, answered by our medical review team.
HALOTHANE is a General Anesthetic that works by Halothane is a volatile halogenated hydrocarbon anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits NMDA and nicotinic acetylcholine receptors, leading to neuronal hyperpolarization and general anesthesia.. DESFLURANE is a General Anesthetic that works by Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HALOTHANE and DESFLURANE depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HALOTHANE is: Induction: 0.5-3% in oxygen or oxygen-nitrous oxide mixture, titrated to effect; Maintenance: 0.5-2% in oxygen or oxygen-nitrous oxide mixture.. The standard adult dose of DESFLURANE is: Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HALOTHANE and DESFLURANE. The risk or severity of adverse effects can be increased when Desflurane is combined with Halothane. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HALOTHANE is classified as Category C. Halothane is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects, but adequate human studies are lacking. First trimester exposure is associated w. DESFLURANE is classified as Category C. Desflurane is not associated with major congenital malformations in the first trimester, but use in the second and third trimesters may cause fetal depression, decreased fetal hear. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.